

KIYATEC appoints Bob Silverman as Board Chairman

KIYATEC, a private company prioritizing the accurate ex vivo prediction of cancer patients' response to drug treatment, has appointed Robert J. Silverman as Chairman of its Board of Directors. Silverman is an experienced executive in the diagnostics and pharmaceutical industries.

Greenville, SC – April 4, 2014

KIYATEC Inc. is pleased to announce the appointment of Robert J. Silverman as Chairman of the Board of Directors of the Company. Mr. Silverman has served on the company's Board of Directors since 2012.

Mr. Silverman has considerable executive-level experience in the diagnostics and pharmaceutical industries. He currently serves as an Operational Partner to Gilde Healthcare, a transatlantic venture investor in fast growing healthcare technology and healthcare services companies with over \$600 million under management. Mr. Silverman currently works with several other companies in a Board and Advisory capacity.

Mr. Silverman is the former CEO of mtm laboratories AG, an in-vitro diagnostics company which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer. He was instrumental in building this company into a global, fully integrated business, with a strong foundation of significant clinical utility and commercial momentum. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of \$270 Million and then facilitated the integration of mtm into Roche.

Prior to mtm laboratories, Mr. Silverman was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytoc Corporation. During his tenure at Cytoc, he served as the Vice President of Marketing and the Vice President of International, and was integral in launching and establishing the core technology (the ThinPrep Pap Test) into the standard of care for cervical cancer screening. Previous positions include Vice-President of Marketing for Pasteur Merieux Connaught, Director of New Product Development for Abbott Laboratories Pharmaceutical Products Division and Management Consultant with Bain and Company.

He earned his Master's degree in Marketing and Finance from Northwestern's Kellogg Graduate School of Management and received his Bachelor of Science degree in Pharmacy from the University of Michigan.

"On behalf of KIYATEC, I am delighted to welcome Bob as Chairman," said Matt Gevaert, CEO. "His wealth of experience as both an executive and director in the diagnostics industry will be instrumental in

successfully taking our company to the next level. We have benefitted greatly from his exemplary service to date, and I see this as KIYATEC getting more of a great thing.”

About KIYATEC Inc.

KIYATEC prioritizes accurate ex vivo prediction of cancer patients’ response to drug treatment, with a focus on data correlation to human clinical outcomes. The company creates and utilizes live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials and clinical diagnostics applications. By accurately predicting patient drug response without ever exposing actual patients to drugs, KIYATEC will create informed drug selection that minimizes clinical trials’ failures and maximizes cancer patient outcomes in the clinic. For more information, please visit www.kiyatec.com or follow KIYATEC on Twitter (@KIYATEC).